Research progress on the characteristics of immune tolerant phase and antiviral therapy in children with chronic hepatitis B

VernacularTitle:儿童慢性乙型肝炎免疫耐受期的特点和抗病毒治疗研究进展
Author: Jing LI ¹ ; Peiyao FAN ; Weiguo HONG ; Min ZHANG ; Fusheng WANG
Author Information

1. 解放军总医院第五医学中心感染病医学部，北京　100039
Keywords: Chronic hepatitis B; Children; Immune tolerance; Antiviral therapy; Clinical cure
From: Chinese Journal of Hepatology 2022;30(11):1259-1265
CountryChina
Language:Chinese
Abstract: Whether or not children with chronic hepatitis B (CHB) in the immune-tolerant phase need to be treated is one of the hot clinical issues that have not yet been clarified. Thus, in order to make clinical antiviral treatment decisions in children with an immune tolerant phase, a comprehensive understanding of the natural history of HBV infection, as well as its relationship with disease progression and whether prompt treatment can alter the natural history and prognosis, is very important. To that end, this article reviews the research progress of clinical antiviral therapy in the immune-tolerant phase for children with chronic hepatitis B over the last decade, while also discussing the treatment's safety, effectiveness, and related immunological mechanisms, so as to clarify the next key step in research orientation, provide direct evidence-based medical evidence for hepatologists to better diagnose and treat, and ultimately improve the clinical cure rate.